Erickson Robert P, McQueen Charlene A, Chau Binh, Gokhale Vijay, Uchiyama Masahi, Toyoda Atsushi, Ejima Fumiwo, Maho Naka, Sakaki Yoshiyuki, Gondo Yoichi
Department of Pediatrics, University of Arizona, 1501 N. Campbell Avenue, P.O. Box 245073, Tucson, AZ 85724, USA.
Biochem Biophys Res Commun. 2008 May 30;370(2):285-8. doi: 10.1016/j.bbrc.2008.03.085. Epub 2008 Mar 26.
Genetic variation in human N-acetyltransferases (NAT) has been implicated in susceptibility to aromatic amine and hydrazine carcinogens and therapeutic drugs. There are mouse models for variability of human NAT1; however mice with genetic differences in Nat1 (corresponding to human NAT2), have not been available. N-Ethyl-N-nitrosourea (ENU) mutagenesis was used to create genetic variation in Nat1. Among a number of mutations identified, a base-pair change substituting threonine for isoleucine at position 95 was recovered and studied. Molecular models suggested that this substitution would alter substrate binding. Analysis of hepatic Nat1 activity with the selective substrate isoniazid showed that there was a significant reduction in enzymatic activity in the homozygous mutants compared to the parental strain.
人类N-乙酰基转移酶(NAT)的基因变异与对芳香胺和肼类致癌物及治疗药物的易感性有关。存在人类NAT1变异性的小鼠模型;然而,尚无在Nat1(对应于人类NAT2)上存在基因差异的小鼠。使用N-乙基-N-亚硝基脲(ENU)诱变在Nat1中产生基因变异。在鉴定出的许多突变中,回收并研究了在第95位将异亮氨酸替换为苏氨酸的碱基对变化。分子模型表明,这种替换会改变底物结合。用选择性底物异烟肼分析肝脏Nat1活性表明,与亲本菌株相比,纯合突变体的酶活性显著降低。